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Abstract
Background—The study was conducted to examine the impact of oral contraceptives (OCs) on
serum antimullerian hormone (AMH) levels by obesity status in reproductive-age women.
Study design—Ovulatory women, ages 18–35 years, of normal (< 25 kg/m2; n = 10) and obese
(> 30 kg/m2; n = 10) body mass index (BMI) received a low-dose OC (20 mcg ethinyl estradiol/100
mcg levonorgestrel) for two cycles. Serum samples obtained at several time points during active pill
use and hormone-free intervals were analyzed for AMH, FSH, LH, estradiol and inhibin B.
Results—AMH levels did not differ by OC cycle day in either BMI group. On average, AMH levels
were 34% lower in the obese group (2.9±2.1 versus 4.4±1.8ng/ml, p<0.05). Modeling to determine
differences in AMH throughout the cycle based on obesity status demonstrated significiantly lower
levels (p<0.05), whereras serum AMH, FSH, LH, estradiol and inhibin B levels revealed no
correlations when all time points were included.
Conclusions—In reproductive-aged women, serum AMH levels do not appear to fluctuate during
OC use but AMH levels are significantly lower in obese women. Lower levels do not appear to be
due to differences in gonadotropin levels or ovarian activity.
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1. Introduction
Antimullerian hormone (AMH) is becoming widely accepted as a clinical marker of ovarian
reserve, the quantity of oocytes remaining. Levels are thought to be the earliest marker of a
decline in ovarian reserve [1], to be a good predictor of poor ovarian response to controlled
ovarian hyperstimulation [2], and to display minimal inter- and intra-cycle variability [3,4].
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Although the AMH assay has been approved for research use only, physicians are checking
levels for clinical use. Fertility centers are not uncommonly using AMH as their preferred
measure of ovarian reserve.
AMH has the potential to be a convenient measure of ovarian reserve in women on oral
contraceptives (OCs). An effective measure of ovarian reserve in women on OCs would be
beneficial for screening oocyte donors and women in their thirties, delaying pregnancy but
concerned about future fertility. Recent studies have shown that AMH levels do not appear to
change after prolonged OC use [5]. However, it is unknown, on which OC cycle day to best
measure ovarian reserve, especially if AMH levels were to fluctuate on a day-to-day basis with
OCs use. In theory, AMH levels could fluctuate with follicular development [6]. We
hypothesized that AMH levels could fluctuate while women are on OCs, depending on the
degree of follicular development.
Additionally, the validity of AMH levels in obese women may also hamper its clinical use.
Recent studies have shown AMH levels to be lower in perimenopausal obese women compared
to perimenopausal non-obese women [7,8]. Differences in AMH were not mirrored by changes
in other markers of ovarian reserve such as follicle-stimulating hormone (FSH) and antral
follicle count [8]. One could argue, however, that this discrepancy may be due to the fact that
AMH is an earlier marker of ovarian aging in perimenopausal women and that differences in
antral follicle count and FSH were not yet observable in this cohort.
It is unknown if differences in AMH in obese and normal BMI women will be observed in a
younger, reproductive cohort, in which ovarian aging would be less likely to have occurred.
We hypothesized that in a younger cohort, AMH levels would be lower in obese women
compared to normal weight women. In this study, we sought to determine if AMH levels
fluctuate in OCs users, to determine if AMH levels differ between obese and normal BMI
reproductive-age women on OCs, and to compare changes in AMH during an OC cycle to
changes in gonadotropins and granulosa cell hormone products (estradiol and inhibin B).
2. Materials and methods
In this exploratory study, regularly menstruating women, ages 18–35 years, of normal (<25
kg/m2, N=10) and obese (>30kg/m2, N=10) body mass index (BMI) were recruited for a study
of OCs and obesity. Evidence of normal ovulatory cycles (luteal phase progesterone ≥ 3 ng/
mL serum) was obtained prior to enrollment. Baseline measurements of height and weight
were obtained for calculation of BMI. Body composition (% body fat) was determined by air
displacement plethysmography. Subjects subsequently initiated a lowdose OC (20 mcg ethinyl
estradiol/100 mcg levonorgestrel) on menstrual cycle day 1 and continued for two cycles.
Serum was subsequently obtained after 21 days of active pills, at the end of the 7-day hormone-
free interval, and twice weekly thereafter in the second cycle until the end of the active pills
for a total of 7 samples per subject (n = 140 samples). FSH, luteinizing hormone (LH), inhibin
B, and estradiol levels were quantified in the serum samples by sensitive and specific
immunoassays. FSH and LH were measured using the automated Immulite chemiluminescent
assay system (Siemens Medical Solutions, Los Angeles, CA). The average interassay CVs
were 10.0% and 7.5%, respectively. Estradiol was measured using an ultra-sensitive
competitive binding radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX).
Inhibin B was measured by ELISA using an enzymatically amplified two-site, two-step,
sandwich-type ELISA (Diagnostic Systems Laboratories, Webster, TX) with an assay
sensitivity of 7 pg/mL; the average interassay CV was 6.9%. AMH was measured for each
subject at all time points using a commercially available ELISA (Diagnostic Systems
Laboratories, Webster, TX); the assay sensitivity is 0.1 ng/mL and the average interassay CV
was 6.5%.
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Informed consent was obtained from all subjects under an OHSU Institutional Review Board
(IRB) approved protocol [9]. Additional consent was not obtained for this secondary analysis
of AMH and inhibin B, as the IRB felt that the analysis fell within the scope of the original
research protocol.
Demographics were compared between the obese and normal groups using a two-sample
Student’s t test. Results are presented as the mean ± standard deviation. As AMH, FSH, and
estradiol were not normally distributed, they were log-transformed prior to analysis. After log
transformation, AMH levels were compared across and between the obese and normal BMI
groups using linear regression with a cluster term to adjust for repeat measures within an
individual. Subsequently, general estimating equation (GEE) models were created with an
interaction term (cycle day × obesity status) to analyze the change in AMH levels across the
OC cycle by obesity status, with a variable for cycle day to analyze the independent effect of
cycle day on AMH levels, and with a variable for obesity status to analyze the independent
effect of obesity on AMH levels. GEE models allow for analysis of data with repeated
measurements on the same subject over time, differing from repeated measure analysis of
variance (MANOVA) in that it does not require an equal number of measurements and equal
time spacing. Similar analyses were conducted with log-transformed FSH and estradiol and
inhibin B. Pair-wise correlations of AMH, inhibin B, the gonadotropins and estradiol were
conducted using Pearsons and Spearman correlation statistic, where appropriate. All analyses
were conducted using STATA 10.0 (College Station, TX).
3. Results
Mean BMI and percent body fat were significantly different between the obese (37.3±6.0kg/
m2 and 50.3±3.5%) and normal (21.9±1.6kg/m2 and 27.6±7.2%) groups (p<0.05). Age did not
differ significantly between the two groups (normal 29±6.3 years versus obese 29±4.9 years).
AMH levels were, on average, 34% lower in the obese group (2.9±2.1 versus 4.4±1.8ng/ml,
p<0.05). In the normal and obese BMI groups, AMH levels did not differ by OC cycle day (p=
0.88 and p=0.43, respectively, Fig. 1A). Across the cycles, the CV of AMH averaged 16.1%
± 7 in the normal group and 16.1%±4.4 in the obese group. Modeling to determine differences
in AMH throughout the OC cycles based on obesity status showed that the obese group had
significantly lower AMH levels across the OC cycles (pobesity<0.05) and that change in AMH
levels across the OC cycle did not differ by obesity status (pobesity×cycle=0.81, Fig. 1A).
After adjusting for repeat measures, average FSH, estradiol, and inhibin B levels did not
significantly differ between the obese and normal groups while on OCs (P= 0.94, 0.1, 0.7,
respectively). However, modeling to determine differences in estradiol levels throughout the
OC cycle based on obesity status showed that the obese group had a significantly higher
estradiol curve during the first two weeks of the second OC cycle (Pobesity<0.05, see Fig. 1B).
In both groups, estradiol levels fluctuated based on cycle day (Pcycle<0.05, Fig. 1B). FSH
differed by cycle day (Pcycle<0.05) but not obesity status (Pobesity=0.9, Fig. 1B). Similarly,
inhibin B levels differed by cycle day (Pcycle<0.001) but did not differ by obesity status
(Pobesity=0.7). No significant correlation was found between gonadotropin, estradiol, or inhibin
levels and AMH when all time points were included. Inhibin B levels were the most highly
correlated with AMH (r=0.23, p=0.09).
4. Discussion
In summary, AMH levels did not appear to fluctuate significantly during OC use. While on
OCs, AMH levels were significantly lower in obese women compared to normal BMI women.
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These differences did not appear to be due to differences in hypothalamic-pituitary-ovarian
activity.
Previous studies have compared menstrual cycle day 3 AMH levels during spontaneous cycles
to those during OC use [5,10,11]. One study found that AMH levels along with FSH levels
were suppressed in the OC cycle [10]; the other two found no significant difference in AMH
levels [5,11]. This discrepancy may be due to the study of an infertile population [10] rather
than the general population [5,11]. Our findings are consistent with findings in spontaneous
cycles. Variations in AMH levels during spontaneous cycles do not appear to be clinically
meaningful or greater than intercycle variability despite follicular development and fluctuating
gonadotropin levels during the menstrual cycle [11].
Our study size was small (only 20 subjects); however, despite repeated testing across the cycle
(7 samples per subject), we failed to see statistically significant fluctuation in values, even on
low-dose OCs. Graphically minor fluctuations were seen during the first 2 weeks of active
pills. Future larger studies could focus on these time points. However, it will be important to
preemptively define what fluctuation size would be deemed clinically meaningful.
We found that AMH levels were lower at every time point in obese OC users. This has been
previously seen in a study of normal cycling, late reproductive-age women [7] on day 3 of a
spontaneous menstrual cycle. In this current study of significantly younger women (29 years
versus 46 years of age), this discrepancy in AMH levels persisted. In the study of Freeman et
al. [7], AMH levels were 65% lower, while in our study the levels were 34% lower. Absolute
differences, however, were larger in our study with a mean difference of 1.5 ng/mL. Using
previous estimates, this difference would translate to menopause occurring 3 years earlier in
obese women [12], a phenomenon that has not been observed.
We sought to determine if lower AMH levels in obese OC users could be attributed to escape
from hypothalamic-pituitary-ovarian suppression. In fact, the obese group was more likely to
show signs of follicular development (exhibited by a higher estradiol curve following a rise in
FSH during the first hormone free-interval) in the second cycle of OCs. However, AMH levels
did not correlate with gonadotropin or estradiol levels. In addition, the pattern of change in
AMH did not mirror changes in FSH, estradiol, or inhibin B in the same cohort of obese
subjects. Thus, we hypothesize that differences in AMH levels may not be related to gross
changes in hypothalamic, pituitary, or ovarian function.
AMH has been shown to inhibit FSH augmentation of CYP19 expression and aromatase
activity [13] in preantral follicles and small antral follicles. AMH levels in larger antral follicles
and periovulatory follicles are suppressed [14]. Perhaps high local aromatase activity and
estrogen to androgen ratios suppress local AMH production [15], allowing for continued
growth of the dominant follicle with the normal decline in FSH. A recent study indirectly
supports this theory; aromatase inhibition leads to increased local AMH production [16]. High
ovarian aromatase activity in obese women could lead to suppression of AMH production and
lower AMH levels. Adipocytokines such as adiponectin may either directly or indirectly alter
granulosa cell AMH production through this mechanism. Adiponectin reportedly inhibits
aromatase activity in the ovary [17]. Obese women have low levels of adiponectin [18].
Of note, inhibin B levels did fluctuate during the OC cycle in both the obese and normal BMI
women. Inhibin B levels rose during the hormone-free interval and declined with the
reinitiation of hormonal active pills in both groups. We did not observe lower inhibin B levels
in the obese cohort. This finding differs from the findings of Gracia et al. [19] who noted
consistently lower inhibin B levels in late reproductive-age, obese women.
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In conclusion, AMH levels appear to be significantly lower in obese OC users compared to
their normal BMI counterparts. Lower levels do not appear to be due to differences in the
hypothalamic-pituitary-ovarian axis activity. The etiology for lower AMH levels in obese
women is still unknown. A larger clinical study is indicated to study the relationship between
AMH and obesity in reproductive-age women. In the meantime, AMH levels should be
interpreted with caution in obese women.
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Hormone levels during OC use in obese and normal groups. Days 1–28 occur during the first
cycle of OCs (days 22–28 are the hormone free interval) and days 29–49 in the second cycle
of OCs. A) AMH levels. Normal weight subjects are shown in solid line box plots and obese
in dashed line box plots. Boxes represent the interquartile range (25%–75%), center lines the
median, and points outliers. B) FSH, inhibin B, and estradiol levels. FSH levels are depicted
with solid lines, inhibin B with dots, and estradiol with dashes. The obese group is depicted
with open triangles and the normal group with closed circles. Points depict mean hormone
levels.
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